224 related articles for article (PubMed ID: 30033087)
1. Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials.
Guhr A; Kobold S; Seltmann S; Seiler Wulczyn AEM; Kurtz A; Löser P
Stem Cell Reports; 2018 Aug; 11(2):485-496. PubMed ID: 30033087
[TBL] [Abstract][Full Text] [Related]
2. Human embryonic and induced pluripotent stem cell research trends: complementation and diversification of the field.
Kobold S; Guhr A; Kurtz A; Löser P
Stem Cell Reports; 2015 May; 4(5):914-25. PubMed ID: 25866160
[TBL] [Abstract][Full Text] [Related]
3. HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives.
Säljö K; Barone A; Mölne J; Rydberg L; Teneberg S; Breimer ME
Sci Rep; 2017 Oct; 7(1):13072. PubMed ID: 29026098
[TBL] [Abstract][Full Text] [Related]
4. Haematopoietic developmental potential of human pluripotent stem cell lines.
Tesařová L; Simara P; Stejskal S; Koutná I
Folia Biol (Praha); 2014; 60 Suppl 1():90-4. PubMed ID: 25369348
[TBL] [Abstract][Full Text] [Related]
5. The safety of human pluripotent stem cells in clinical treatment.
Simonson OE; Domogatskaya A; Volchkov P; Rodin S
Ann Med; 2015; 47(5):370-80. PubMed ID: 26140342
[TBL] [Abstract][Full Text] [Related]
6. Power-laws and the use of pluripotent stem cell lines.
Schuldt BM; Guhr A; Lenz M; Kobold S; MacArthur BD; Schuppert A; Löser P; Müller FJ
PLoS One; 2013; 8(1):e52068. PubMed ID: 23300961
[TBL] [Abstract][Full Text] [Related]
7. Sialyl-lactotetra, a novel cell surface marker of undifferentiated human pluripotent stem cells.
Barone A; Säljö K; Benktander J; Blomqvist M; Månsson JE; Johansson BR; Mölne J; Aspegren A; Björquist P; Breimer ME; Teneberg S
J Biol Chem; 2014 Jul; 289(27):18846-59. PubMed ID: 24841197
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of medium, matrix, and exogenous factors on the adhesion and growth of human pluripotent stem cells under defined, xeno-free conditions.
Meng G; Liu S; Rancourt DE
Stem Cells Dev; 2012 Jul; 21(11):2036-48. PubMed ID: 22149941
[TBL] [Abstract][Full Text] [Related]
9. Human embryonic stem cell lines and their use in international research.
Löser P; Schirm J; Guhr A; Wobus AM; Kurtz A
Stem Cells; 2010 Feb; 28(2):240-6. PubMed ID: 20027651
[TBL] [Abstract][Full Text] [Related]
10. Challenges and approaches to the culture of pluripotent human embryonic stem cells.
Skottman H; Narkilahti S; Hovatta O
Regen Med; 2007 May; 2(3):265-73. PubMed ID: 17511563
[TBL] [Abstract][Full Text] [Related]
11. A Manually Curated Database on Clinical Studies Involving Cell Products Derived from Human Pluripotent Stem Cells.
Kobold S; Guhr A; Mah N; Bultjer N; Seltmann S; Seiler Wulczyn AEM; Stacey G; Jie H; Liu W; Löser P; Kurtz A
Stem Cell Reports; 2020 Aug; 15(2):546-555. PubMed ID: 32679065
[TBL] [Abstract][Full Text] [Related]
12. Production of human pluripotent stem cell therapeutics under defined xeno-free conditions: progress and challenges.
Fan Y; Wu J; Ashok P; Hsiung M; Tzanakakis ES
Stem Cell Rev Rep; 2015 Feb; 11(1):96-109. PubMed ID: 25077810
[TBL] [Abstract][Full Text] [Related]
13. Pluripotent Stem Cells in Clinical Setting-New Developments and Overview of Current Status.
Ilic D; Ogilvie C
Stem Cells; 2022 Sep; 40(9):791-801. PubMed ID: 35671338
[TBL] [Abstract][Full Text] [Related]
14. Characterization of six new human embryonic stem cell lines (HSF7, -8, -9, -10, -12, and -13) derived under minimal-animal component conditions.
Chavez SL; Meneses JJ; Nguyen HN; Kim SK; Pera RA
Stem Cells Dev; 2008 Jun; 17(3):535-46. PubMed ID: 18513167
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.
Lee MO; Moon SH; Jeong HC; Yi JY; Lee TH; Shim SH; Rhee YH; Lee SH; Oh SJ; Lee MY; Han MJ; Cho YS; Chung HM; Kim KS; Cha HJ
Proc Natl Acad Sci U S A; 2013 Aug; 110(35):E3281-90. PubMed ID: 23918355
[TBL] [Abstract][Full Text] [Related]
16. Democracy derived? New trajectories in pluripotent stem cell research.
Scott CT; McCormick JB; DeRouen MC; Owen-Smith J
Cell; 2011 Jun; 145(6):820-6. PubMed ID: 21663787
[TBL] [Abstract][Full Text] [Related]
17. Generation of high-level stable transgene expressing human embryonic stem cell lines using Chinese hamster elongation factor-1 alpha promoter system.
Chan KK; Wu SM; Nissom PM; Oh SK; Choo AB
Stem Cells Dev; 2008 Aug; 17(4):825-36. PubMed ID: 18788934
[TBL] [Abstract][Full Text] [Related]
18. Gene targeting in human pluripotent stem cells.
Liu Y; Rao M
Methods Mol Biol; 2011; 767():355-67. PubMed ID: 21822888
[TBL] [Abstract][Full Text] [Related]
19. Hadassah, provider of "Regulatory-Ready" pluripotent clinical-grade stem cell banks.
Tannenbaum SE; Singer O; Gil Y; Berman-Zaken Y; Ilouz N; Khaner H; Haimov M; Reubinoff BE
Stem Cell Res; 2020 Jan; 42():101670. PubMed ID: 31838378
[TBL] [Abstract][Full Text] [Related]
20. Primed pluripotent cell lines derived from various embryonic origins and somatic cells in pig.
Park JK; Kim HS; Uh KJ; Choi KH; Kim HM; Lee T; Yang BC; Kim HJ; Ka HH; Kim H; Lee CK
PLoS One; 2013; 8(1):e52481. PubMed ID: 23326334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
